Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. Current Liabilities for the quarter ending September 30, 2024

Biomea Fusion, Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Biomea Fusion, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 16.21 M, a 28.76% change year over year.
Biomea Fusion, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 12.59 M, a 123.17% change year over year.
Biomea Fusion, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 5.64 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years